Nevan 0.1% (Ophthalmic Suspension)
5 ml drop: ৳ 150.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Nepafenac |
| Company | Aristopharma ltd |
| Also available as |
Product Title
- Nevan 0.1% Sterile Ophthalmic Suspension
- Nevan 0.3% Sterile Ophthalmic Suspension
Categories
- Ophthalmic Medication
- Nonsteroidal Anti-Inflammatory Drug (NSAID)
- Post-operative Ocular Pain Treatment
- Cataract Surgery Medication
Description
- Treats post-operative ocular pain and inflammation
- Inhibits surgery induced miosis
- Prevents post-operative cystoid macular edema (CME)
- Pharmacologically converts to Amfenac, a potent NSAID
- Available in 0.1% and 0.3% formulations
- Contraindicated in patients with hypersensitivity to ingredients or other NSAIDs
- Reported side effects include foreign body sensation, ocular discomfort, and ocular hyperemia
- Caution in patients with bleeding tendencies or receiving medications affecting bleeding time
Dosage and Administration
- Instill 1 drop 3 times daily for 0.1% suspension prior to cataract surgery
- Instill 1 drop 3 times daily for 0.1% suspension for surgery induced miosis
- Instill 1 drop 3 times daily for 0.1% suspension for prevention of post-operative CME
- Instill 1 drop once daily for 0.3% suspension prior to cataract surgery, with additional drop 30 to 120 minutes before surgery
Mode of Action
- Penetrates the cornea and is converted to Amfenac by ocular tissue hydrolase
- Inhibits action of cyclooxygenase enzyme required for prostaglandin synthesis
Contraindications
- Hypersensitivity to any of the ingredients or other NSAIDs
Side Effects
- Foreign body sensation
- Lid margin crusting
- Ocular discomfort
- Ocular hyperemia
Pregnancy and Lactation
- Use during pregnancy only if potential benefit justifies potential risk to fetus
- Use in lactation cautionary due to unknown excretion in human milk
Precautions
- Caution in patients with known bleeding tendencies or receiving medications affecting bleeding time
Pediatric Uses
- Safety and effectiveness not established in pediatric patients below 18 years of age
Elderly Patients
- No overall differences in safety or effectiveness observed between elderly and younger patients
Therapeutic Class
- Ophthalmic Non-Steroid Drugs